Clinical Trials Browser

Phase 1/2 × Inflammatory Breast Neoplasms × 90 days × Clear all

NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms